Mr. Martin A. Vogelbaum is Lead Independent Director at CARA Therapeutics, Inc., Independent Director at Inotek Pharmaceuticals Corp., Partner at Rho Ventures and Non-Managing Member at RMV VI LLC.
He is on the Board of Directors at CARA Therapeutics, Inc., Inotek Pharmaceuticals Corp., Nora Therapeutics, Inc. and SARcode Bioscience, Inc.
Mr. Vogelbaum was previously employed as General Partner by Oxford Bioscience Partners and General Partner by Apple Tree Partners.
He also served on the board at NephroGenex, Inc., Middlebrook Pharmaceuticals, Inc., Nuvelo, Inc., Gloucester Pharmaceuticals, Inc. and Mersana Therapeutics, Inc.
He received his AB in biology and history degree from Columbia University.